Could a menopause drug cool hot flashes in men with prostate cancer?
NCT ID NCT06972875
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called fezolinetant, already approved for hot flashes in menopausal women, to see if it can reduce hot flashes in men with prostate cancer who are on hormone-lowering therapy. About 32 men will take the drug daily for 28 days. The goal is to measure how much hot flash symptoms improve and to check for any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fezolinetant
What this could lead to
If it works, this could offer a non-hormonal option to manage hot flashes in men undergoing prostate cancer treatment, improving daily comfort and treatment adherence.
What could go wrong
This is a small, early-phase study with only 32 participants, so results may not apply broadly. The drug is approved for women but not yet proven safe or effective in men.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Vermont Medical Center
RECRUITINGBurlington, Vermont, 05401, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••